ECOR

Dr. Peter Staats to Host Analyst Day on the Science Behind gammaCore™ Non-Invasive Vagus Nerve Stimulation (nVNS) on Tuesday, November 21, 2023

Retrieved on: 
Wednesday, November 15, 2023

Analyst Day: “Accessing the Power of Vagus Nerve Stimulation with gammaCore™”Date: Tuesday, November 21, 2023Time: 1:30pm – 2:30pm ESTRegistration: https://electrocore.zoom.us/webinar/register/WN_wcHtB4caT--D58SYPiyryw

Key Points: 
  • ROCKAWAY, N.J., Nov. 15, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that the Company’s Chief Medical Officer, Dr. Peter Staats will host an analyst day entitled “Accessing the Power of Vagus Nerve Stimulation with gammaCore™” on November 21, 2023 at 1:30pm EST.
  • The webinar will cover the nVNS mechanism of action and potential pipeline of indications using the company’s proprietary nVNS technology platform that is embodied in its gammaCore product.
  • Participants interested in listening to the webinar can register by clicking here .
  • Following the live presentation, a playback of the webinar will be available on the “Investors” section of the company’s website at: www.electrocore.com.

ECOR Global Inc. Secures Funding from Phalanx Impact Partners to Accelerate Capital Projects

Retrieved on: 
Monday, November 20, 2023

Phalanx Impact Partners (“Phalanx”) , a US-based impact driven private equity firm, today announced they have made an investment in ECOR Global Inc .

Key Points: 
  • Phalanx Impact Partners (“Phalanx”) , a US-based impact driven private equity firm, today announced they have made an investment in ECOR Global Inc .
  • (“ECOR” or “the Company”), an emerging leader in the manufacture of sustainable materials and circular solutions for the building products and packaging markets.
  • The Phalanx funding marks an important milestone for ECOR as the company prepares for a significant increase in production capacity and distribution of its proprietary materials solutions.
  • The funding from Phalanx will enable ECOR to accelerate its near-term development initiatives and complete the design and commercial work for its first planned U.S. facility and further expansion thereafter.

Ecora Resources PLC to Present at the Harbor Access Global SMID Cap Investor Conference November 16th

Retrieved on: 
Wednesday, November 8, 2023

LONDON, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Ecora Resources PLC (LSE/TSX: ECOR.

Key Points: 
  • LONDON, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Ecora Resources PLC (LSE/TSX: ECOR.
  • OTCQX: ECRAF), based in London, focused on royalties in commodities that support a sustainable future, today announced that Marc Bishop Lafleche, CEO, will present live at the Global SMID Cap Investor Conference, hosted by Harbor Access Investor Relations and VirtualInvestorConferences.com, on November 16th, 2023.
  • This will be a live, interactive online event where investors are invited to ask the company questions in real-time.
  • It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates.

electroCore to Participate in Canaccord Genuity’s MedTech, Diagnostics and Digital Health & Services Forum

Retrieved on: 
Tuesday, November 7, 2023

ROCKAWAY, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Company CEO, Dan Goldberger, is scheduled to attend the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum taking place at the Westin NY Grand Central on November 16, 2023.

Key Points: 
  • ROCKAWAY, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Company CEO, Dan Goldberger, is scheduled to attend the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum taking place at the Westin NY Grand Central on November 16, 2023.
    electroCore will host 1x1 investor meetings on November 16, 2023.
  • Please contact your Canaccord representative to schedule a 1x1 meeting.

Data Highlighting Non-invasive Vagus Nerve Stimulation (nVNS) for Treatment of Symptoms of Gastroparesis Presented at 2023 American College of Gastroenterology Annual Meeting

Retrieved on: 
Tuesday, October 24, 2023

The primary endpoint was reducing the use of antinausea medications by using nVNS as the primary rescue treatment for nausea exacerbations.

Key Points: 
  • The primary endpoint was reducing the use of antinausea medications by using nVNS as the primary rescue treatment for nausea exacerbations.
  • The study showed nVNS reduced the use of rescue pills per day by more than 50% (p=0.0007; Figure 1).
  • This benefit was maintained throughout each 4-week treatment period of the crossover study as well as during the two, two-week, washout periods.
  • Overall significance (Type 3 F test): p=0.0007
    Presentation 68: Non-Invasive Vagal Nerve Stimulation Reduces Nausea Rescue Medication in Patients With Gastroparesis and Related Disorders, With Additional Benefits on Multiple Other Associated Symptom

Oragenics Announces Appointment of Bruce Cassidy and John Gandolfo to Board of Directors

Retrieved on: 
Wednesday, October 18, 2023

Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) announced the appointments of Bruce Cassidy and John Gandolfo to the Board of Directors effective October 4, 2023.

Key Points: 
  • Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) announced the appointments of Bruce Cassidy and John Gandolfo to the Board of Directors effective October 4, 2023.
  • “We are delighted to welcome Bruce Cassidy and John Gandolfo to the Oragenics Board,” said Charlie Pope, Chairman of Oragenics.
  • I look forward to working with the Oragenics Board and the Odyssey team to help steer the new strategy and direction of the Company,” said Bruce Cassidy.
  • I am happy to continue my involvement as a member of Oragenics Board,” said John Gandolfo.

electroCore Announces Two-Year Extension of gammaCore™ Device Listing in the NHS Supply Chain Catalogue

Retrieved on: 
Tuesday, October 17, 2023

ROCKAWAY, N.J., Oct. 17, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial stage bioelectronic medicine and wellness company, announced today that gammaCore therapy will continue to be listed in the United Kingdom’s National Health Service (NHS) Supply Chain catalogue for an additional two years through March 17, 2026.

Key Points: 
  • ROCKAWAY, N.J., Oct. 17, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial stage bioelectronic medicine and wellness company, announced today that gammaCore therapy will continue to be listed in the United Kingdom’s National Health Service (NHS) Supply Chain catalogue for an additional two years through March 17, 2026.
  • The listing, which commenced on June 4, 2019, was scheduled to terminate on March 18, 2024.
  • “We are delighted the NHS Supply Chain intends to continue to include the gammaCore device within their framework agreement, commencing March 2024 through March 2026 with an option to extend for a further 2 years,” stated Mitch DeShon, Vice President of Global Sales & Business Development at electroCore.
  • “Inclusion in this catalogue helps ensure gammaCore therapy is broadly accessible to patients across the UK who may benefit from non-invasive vagus nerve stimulation and adds increased validation to the benefits realized by patients in the UK using gammaCore therapy.”

electroCore Expands Intellectual Property Portfolio for Non-Invasive Vagus Nerve Stimulation (nVNS) Technology

Retrieved on: 
Wednesday, October 11, 2023

U.S. Patent No.

Key Points: 
  • U.S. Patent No.
  • 11,779,756 entitled “Systems and Methods for Vagal Nerve Stimulation” was issued on October 10, 2023, and is generally related to a preferable treatment paradigm for nVNS that involves applying a single dose of stimulation for about 90 seconds to about 150 seconds, 2-4 times during a 24-hour period.
  • “Our intellectual property portfolio continues to grow,” stated Dan Goldberger, Chief Executive Officer of electroCore.
  • “This new patent strengthens our position around the application of non-invasive vagus nerve stimulation, and how frequently nVNS may be used by a patient or customer looking for relief.”

Data Highlighting Non-Invasive Vagus Nerve Stimulation (nVNS) for Treatment of Acute Neurological Injury Presented at 2023 World Stroke Congress

Retrieved on: 
Tuesday, October 10, 2023

ROCKAWAY, N.J., Oct. 10, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced top line data from two abstracts being presented at the 15th World Stroke Congress held October 10-12, 2023, in Toronto, Canada on the possible role of nVNS in the treatment of acute neurological injuries.

Key Points: 
  • Our data suggests that nVNS is safe and effective in reducing pain and potentially the use of other acute pain medications, including opioids in the immediate aftermath of a SAH.
  • NOVIS is a prospective randomized clinical trial with blinded outcome assessment being conducted at the Leiden University Medical Center (Leiden, The Netherlands).
  • 150 patients with ischemic stroke are being randomly allocated (1:1) to nVNS for five days in addition to standard treatment versus standard treatment alone.
  • The strong mechanistic rational for nVNS as a potentially neuroprotective and anti-inflammatory treatment for acute neurological injury is further supported by this data showing the continued efficacy of nVNS for the treatment of pain.

electroCore to Announce Third Quarter Financial Results on Wednesday, November 8

Retrieved on: 
Monday, October 9, 2023

ROCKAWAY, N.J., Oct. 09, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial results for the third quarter ended September 30, 2023, after the close of the market on Wednesday, November 8, 2023.

Key Points: 
  • ROCKAWAY, N.J., Oct. 09, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial results for the third quarter ended September 30, 2023, after the close of the market on Wednesday, November 8, 2023.
  • Management will host a conference call and webcast at 4:30 PM EST to discuss the financial results and answer questions.